How should healthcare organisations control tracking technologies in patient portals?

They should treat patient portals as sensitive execution environments and block or tightly restrict scripts that can observe form inputs, session state, or page content. Contract terms matter, but the real control is whether third-party code can access protected health information at runtime. Inventory every tag, test authenticated pages separately, and remove unnecessary collection paths.

Why This Matters for Security Teams

Patient portals are not ordinary marketing pages. They handle login workflows, appointment details, lab results, billing data, and sometimes messaging that can expose protected health information. Tracking technologies become a security and privacy issue when they can see authenticated page content, capture keystrokes, or send session-linked data to third parties. That makes governance, procurement, and web application security part of the same control problem. NIST SP 800-53 Rev 5 Security and Privacy Controls provides a useful control baseline, but healthcare teams still need to decide which scripts are allowed to execute after login and which must be removed entirely.

The common mistake is treating consent banners or vendor contract language as a sufficient safeguard. That framing misses runtime behavior. If a tag manager or analytics library can read form fields, page text, or session tokens, the organisation has already created a disclosure path, even if the vendor claims not to retain sensitive data. Security, privacy, and compliance teams need a shared inventory of every tracker, plus testing that reflects authenticated use cases rather than public homepage browsing. In practice, many healthcare organisations discover tracking risk only after a privacy review or incident response inquiry, rather than through intentional portal design.

How It Works in Practice

Effective control starts with classifying each tracker by purpose, data access, and execution context. A patient portal should have a much narrower allowance set than a public website. Current guidance suggests treating authenticated sessions as high-risk contexts because the page may contain regulated health data, identifiers, and operational details that can be exposed through third-party JavaScript, pixels, or embedded widgets. The implementation goal is not only to know what is on the page, but also what can be observed at runtime.

A practical control sequence looks like this:

• Inventory every tag, script, pixel, and embedded component, including those loaded by a tag manager.
• Test portal pages after login, not only unauthenticated landing pages.
• Block scripts that can read form inputs, URL parameters with sensitive content, or page elements containing protected data.
• Separate essential functional code from analytics and advertising code.
• Review retention, onward transfer, and access paths for any data a tracker can collect.

Security teams should align browser-side controls with web application governance, including content security policy, subresource integrity where appropriate, and strict change control for portal releases. Privacy teams should verify that notices and contracts match the actual data flow, because contractual language does not neutralise a technical collection path. For control mapping, the NIST privacy and access-control families are a strong baseline, and the broader monitoring approach in OWASP guidance can help teams identify client-side abuse patterns in complex web applications. See OWASP Web Security Testing Guide for testing methods that can surface client-side exposure paths.

These controls tend to break down when a portal relies on third-party widgets for core functions such as scheduling, payments, telehealth launch flows, or identity verification, because the business dependency makes it difficult to isolate or remove risky code quickly.

Common Variations and Edge Cases

Tighter tracking controls often increase implementation overhead, requiring organisations to balance patient privacy against product analytics, revenue reporting, and user experience measurement. The tradeoff is real: aggressive blocking can reduce visibility into portal performance, but permissive tracking can create avoidable exposure of sensitive health information.

There is no universal standard for this yet, so the best answer depends on how the portal is built and what data it exposes. For example, a public symptom-checker page may tolerate limited analytics if no identifiable health data is present, while an authenticated results portal should be far more restrictive. Browser-based monitoring, session replay, and heatmap tools deserve particular scrutiny because they can record text, interactions, and navigation paths that reveal PHI even when the vendor claims to mask fields. For identity-heavy workflows, portal telemetry can also intersect with account recovery, fraud detection, and privileged support access, so teams should ensure those functions do not widen collection beyond necessity. The CISA website security guidance is useful when establishing safer web application practices, while healthcare organisations should still apply internal data minimisation rules before any tracker is approved.

Where a portal serves multiple entities or tenants, consent and data-sharing decisions become more complex because one user journey may traverse several processors and sub-processors. In those cases, the right control is often not merely disclosure, but architectural separation and minimisation of what client-side code can observe.

Related resources from NHI Mgmt Group

• How should healthcare organisations control access to patient data effectively?
• How should healthcare organisations prevent account takeover in patient portals?
• How should healthcare organisations govern non-human identities that handle patient data?
• How should healthcare organisations reduce patient misidentification at intake?